IL13 and Alzheimer disease: While being highly expressed in untreated AD samples of the trunk and head/neck area, these chemokines were consistently downregulated in DAHND (Fig. 5D, Supplementary Data 4), suggesting active inhibition of type 2-associated inflammation by dupilumab, despite retained IL13 upregulation in multiple T cell populations (Fig. 3).